X-linked Lymphoproliferative Disease (XLP) (DBCOND0036035)

Identifiers

Synonyms

X-Linked Lymphoproliferative Syndrome / XLP / X-Linked Lymphoproliferative Disease / X-Linked Lymphoproliferative Disorders / X-Linked Lymphoproliferative Disorder / Immunodeficiency following hereditary defective response to Epstein-Barr virus / Duncan syndrome / X-linked lymphoproliferative syndrome (disorder)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00368355	T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts	Alemtuzumab Cyclophosphamide Cytarabine	treatment	2	completed
NCT00006054	Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies	Busulfan Cyclophosphamide Cyclosporine Etoposide Methotrexate Methylprednisolone Prednisone	treatment	Not Available	terminated
NCT00006056	Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders	Busulfan Cyclophosphamide Cyclosporine Etoposide Filgrastim Methotrexate	treatment	Not Available	unknown_status
NCT01821781	Immune Disorder HSCT Protocol	Alemtuzumab Fludarabine Melphalan Thiotepa	treatment	2	recruiting
NCT05005975	Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)	Dersimelagon	treatment	3	active_not_recruiting
NCT02979249	Oral Iron for Erythropoietic Protoporphyrias	Ferrous sulfate anhydrous	treatment	Not Available	completed
NCT04402489	Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria	Dersimelagon	treatment	3	completed
NCT01688895	Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact	No drug interventions	Not Available	Not Available	completed
NCT02512679	Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells	Cyclophosphamide	treatment	2	terminated
NCT00359411	Genetic Studies of X-linked Lymphoproliferative Disease	No drug interventions	Not Available	Not Available	completed
NCT01652092	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies	Alemtuzumab Busulfan Coenzyme M Cyclophosphamide Fludarabine Melphalan	treatment	Not Available	recruiting
NCT01494103	Administration of Donor T Cells With the Caspase-9 Suicide Gene	Rimiducid	treatment	1	active_not_recruiting
NCT03513328	Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation	Thiotepa	treatment	1 / 2	completed
NCT00176826	T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders	Busulfan Cyclophosphamide	treatment	2 / 3	terminated
NCT00176865	Stem Cell Transplant for Immunologic or Histiocytic Disorders	Alemtuzumab Antilymphocyte immunoglobulin (horse) Cyclosporine Fludarabine Human immunoglobulin G Melphalan Mycophenolate mofetil	treatment	2	completed